ConcertAI
Founded Year
2017Stage
Series C | AliveTotal Raised
$320MValuation
$0000Last Raised
$150M | 3 yrs agoRevenue
$0000Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-57 points in the past 30 days
About ConcertAI
ConcertAI specializes in clinical artificial intelligence and real-world data products within the healthcare sector. The company offers a suite of AI-driven solutions and services designed to optimize clinical trials, provide predictive patient insights, and support commercial healthcare solutions. ConcertAI primarily serves the oncology research and clinical development sectors. It was founded in 2017 and is based in Cambridge, Massachusetts.
Loading...
ESPs containing ConcertAI
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The real-world data providers market offers a variety of value propositions to the pharmaceutical industry, drug labs, and healthcare organizations. It provides access to diverse patient populations, longitudinal real-world data, and patient-powered or EHR-powered controls that can replicate real-world scenarios. This can help shorten drug development timelines, reduce patient recruitment burdens …
ConcertAI named as Outperformer among 15 other companies, including IQVIA, Tempus, and Datavant.
Loading...
Research containing ConcertAI
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned ConcertAI in 4 CB Insights research briefs, most recently on Aug 21, 2024.
Aug 21, 2024
The clinical trials tech market map
Expert Collections containing ConcertAI
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ConcertAI is included in 8 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,276 items
AI 100 (All Winners 2018-2025)
100 items
The winners of the 4th annual CB Insights AI 100.
Conference Exhibitors
5,302 items
Digital Health 50
150 items
The winners of the second annual CB Insights Digital Health 150.
Digital Health
11,408 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
ConcertAI Patents
ConcertAI has filed 1 patent.
The 3 most popular patent topics include:
- artificial neural networks
- classification algorithms
- machine learning
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/29/2021 | Machine learning, Artificial neural networks, Classification algorithms, Machine learning algorithms, Statistical classification | Application |
Application Date | 10/29/2021 |
|---|---|
Grant Date | |
Title | |
Related Topics | Machine learning, Artificial neural networks, Classification algorithms, Machine learning algorithms, Statistical classification |
Status | Application |
Latest ConcertAI News
Jun 25, 2025
EINPresswire.com / -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034 The AI in pharma market size has shown exponential growth in recent years. Current data shows its jump from $2.92 billion in 2024 to an estimated $3.8 billion in 2025 with a compound annual growth rate CAGR of 30.1%. This surge in the historic period can be attributed to the increased adoption of artificial intelligence AI for cost efficient drug discovery and the expanding implementation of AI in radiology. As For The Future, How Is The AI In Pharma Market Anticipated To Grow? The AI in pharma market size is forecasted for substantial growth in the upcoming years. Estimated numbers point towards a growth to $9.64 billion in 2029 at a compound annual growth rate CAGR of 26.2%. Several factors contribute to this upswing in the forecast period, one of which is the adoption of cloud-based applications and services by pharma companies, alongside increasing healthcare expenditure and burgeoning government support for AI development. We also foresee major trends in the forecast period including the introduction of generative AI in pharma, the increasing use of AI in molecular target identification, and the integration of AI in the drug screening process. Other anticipated developments include advancements in AI tools for the pharmaceutical industry, growing investments targeted towards the development of new product solutions, and strategic partnerships and collaborations among market players. Get Your Free Sample Market Report: What Are The Key Drivers Of The AI In Pharma Market Going Forward? The rising adoption of cloud-based applications and services by pharmaceutical companies is anticipated to fuel the growth of the AI in pharma market. These cloud-based drug discovery platforms utilize cutting-edge research and development capabilities in the pharmaceutical industry. They leverage the potential of data analytics and cloud computing technologies to streamline drug discovery procedures, propelling the efficiency, economy, and collaboration of these processes. Pharmaceutical companies, being significant market participants and end-users of these frameworks, benefit from the secure data storage options these platforms provide, allowing the handling of large volumes of clinical, chemical, biological data. The key players shaping the AI in pharma market include industry giants like Concerto HealthAI, Alphabet Inc., OWKIN, Nvidia Corporation, PathAI, Insilico Medicine, Exscientia, Microsoft Corporation, XtalPi, Intel, Standigm, and Takeda Pharmaceutical Company Ltd. Others include Otsuka Pharmaceutical Co. Ltd., China National Pharmaceutical Group Co. Ltd. Sinopharm, Jiangsu Hengrui Medicine Co. Ltd, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Sun Pharma, Alliance Pharm Pte Ltd., Shanghai Pharmaceuticals, DeepMind, GlaxoSmithKline, Sanofi, Bayer, Renalytix AI, Merck, AstraZeneca, Iktos, Benevolent AI, Novartis, Ardigen, Botkin, Webiomed, Care Mentor AI, Diagnocat Order Your Report Now For A Swift Delivery: https://www.thebusinessresearchcompany.com/report/ai-in-pharma-global-market-report What Are The Emerging Trends In The AI In Pharma Market? In terms of emerging trends, companies in the market are increasingly directing their focus towards the use of generative AI in pharma to improve medical consultations. Generative AI, a subfield of artificial intelligence, creates new data instances that resemble existing data. This technology's introduction into the pharmaceutical industry holds the potential to revolutionize drug discovery and development and medical records management. A deep dive into the segmentation of the AI in pharma market reveals the following main sectors: 1 By Technology: Context-Aware Processing, Natural Language Processing, Querying Method, Deep Learning 2 By Drug Type: Small Molecule, Large Molecules 3 By Application: Diagnosis, Clinical Trial Research, Drug Discovery, Research and Development, Epidemic Prediction Further dissection of these sectors gives rise to subsegments: 1 By Context-Aware Processing: Real-Time Data Processing, Contextual Recommendation Systems, Adaptive Learning Systems 2 By Natural Language Processing NLP: Text Analytics And Sentiment Analysis, Chatbots And Virtual Assistants, Document And Data Mining 3 By Querying Method: Structured Querying, Unstructured Querying, Semantic Search Technologies What Are The Regional Insights Into The AI In Pharma Market? In terms of regional performance, North America held the lion's share in the AI in pharma market in 2024. However, the AI in pharma market report has a global coverage extending to Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa. Browse Through More Similar Reports By The Business Research Company: Pharma Microbiology Testing Kits Global Market Report 2025
ConcertAI Frequently Asked Questions (FAQ)
When was ConcertAI founded?
ConcertAI was founded in 2017.
Where is ConcertAI's headquarters?
ConcertAI's headquarters is located at 1120 Massachusetts Avenue, Cambridge.
What is ConcertAI's latest funding round?
ConcertAI's latest funding round is Series C.
How much did ConcertAI raise?
ConcertAI raised a total of $320M.
Who are the investors of ConcertAI?
Investors of ConcertAI include Sixth Street Partners, AllianceBernstein, Maverick Ventures Israel, Declaration Partners, SymphonyAI and 3 more.
Who are ConcertAI's competitors?
Competitors of ConcertAI include Mango Sciences, Aetion, Mendel AI, Zephyr AI, Holmusk and 7 more.
Loading...
Compare ConcertAI to Competitors
Owkin is an AI biotechnology company that employs artificial intelligence to improve drug discovery and development in the biopharmaceutical sector. The company specializes in AI-based identification of new treatments, clinical trial optimization, and diagnostic tool creation, while ensuring patient privacy through federated learning techniques. Owkin serves the biopharma and academic research communities. It was founded in 2016 and is based in New York, New York.
Promptly Health offers real-world evidence solutions within the healthcare sector. The company provides services that include generating knowledge from clinical, socio-economic, and claims data, as well as collecting longitudinal patient-reported data and digital biomarkers. Promptly Health serves life sciences, healthcare providers, and healthcare payers. It was founded in 2017 and is based in Porto, Portugal.
Verantos specializes in real-world evidence within the life sciences sector. The company has a platform that combines various real-world data sources to produce research-grade evidence, using clinical narrative data and artificial intelligence technology. This evidence is used for market access, medical affairs, and regulatory initiatives across therapeutic areas. It was founded in 2015 and is based in Menlo Park, California.
Aetion provides real-world evidence solutions within the healthcare sector. The company offers software and services that analyze real-world data to provide insights on the safety, effectiveness, and value of medical treatments and technologies. It's clientele includes biopharma companies and government agencies to inform health care decisions and guide product development. It was founded in 2012 and is based in New York, New York. In May 2025, Aetion was acquired by Datavant.
Clarify Health specializes in healthcare analytics within the healthcare technology sector. Its offerings include analytics and insights that assist healthcare providers, payers, tech and services organizations, and life sciences companies in their operations. The company serves the healthcare industry, including hospitals, health systems, insurance plans, and pharmaceutical companies. It was founded in 2015 and is based in San Francisco, California.
MediMergent focuses on the collection and analysis of real-world evidence (RWE) in the healthcare field. The company provides solutions for patient engagement, clinical trial support, and population health analytics, aimed at integrating patient feedback into healthcare decision-making. MediMergent serves pharmaceutical and life science companies, health insurers, payers, and data analytics aggregators. It was founded in 2014 and is based in Rockville, Maryland.
Loading...